## **FACSIMILE COVER SHEET**

## SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association 2421 N.W. 41st Street Suite A-1 Gainesville, FL 32606 OFFICIAL

FAX RECEIVED

JUN 26 2003

**GROUP 1600** 

Telephone (352) 375-8100 Facsimile (352) 372-5800

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named below. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

TO:

Examiner Shanon A. Foley

COMPANY:

U. S. Patent Office, Group Art Unit 1648

**FAX NO.:** 

(703) 308-4242

FROM:

Jeff Lloyd

DATE:

June 25, 2003

NUMBER OF PAGES (INCLUDING COVER SHEET): 8

MESSAGE:

Re:

Serial No. 09/807,783

FREEZE-DRIED HEPATITIS A ATTENUATED LIVE VACCINE AND ITS STABILIZER

Our Docket No.: CCP-100

Attached hereto is

Amendment Under 37 CFR §1.111

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.

P. 02

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on 25 June 2003

AMENDMENT UNDER 37 CFF
Patent Application
EXAMINING GROUP 1648
Docket No. CCP-100

Scrial No. 09/807,783

leff Llovil, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Shanon Folcy

Art Unit

1648

Applicant(s)

Jingye Liu et al.

Serial No.

09/807,783

Filed

April 17, 2001

For

Freeze-Dried Hepatitis A Attenuated Live Vaccine and its Stabilizer

Assistant Commissioner for Patents Washington, D.C. 20231

## AMENDMENT UNDER 37 CFR §1.111

Sir:

In response to the Office Action mailed March 25, 2003, please amend the application identified above as follows:

## In the claims:

- 1. (previously amended) A stabilized lyophilized hepatitis A live vaccine formulation comprising prophylactically effective titers of live attentuated hepatitis A virus and a stabilizer, wherein said stabilizer is present in the vaccine formulation at a concentration sufficient to stabilize the hepatitis A virus against heat inactivation.
- wherein said live attentuated hepatitis A virus is prepared from the wild-type HAV, strain L-A-I.
  - · 3. (previously amended) A stabilized lyophilized hepatitis A live vaccine formulation according to claim 1, wherein said stabilizer for lyophilized live hepatitis A virus comprises human scrum albumin or gelatin or both of them; trehalose; at least one amino acid selected from the group consisting of